This blog explores physician recapitalization transactions and how complex they are and their myriad issues. At Foley, in our representation of both investors in, and sellers of, physician practices, we note how often tax issues become gating items that drive the structural aspects of the transaction.
This resource provided by Foley & Lardner LLP covers the DOJ’s announcement on February 6th of their withdrawal of the 2011 Statement of Antitrust Enforcement Policy Regarding Accountable Care Organizations Participating in the Medicare Shared Savings Program (2011 ACO Statement) in addition to two other health care antitrust policy statements.
Foley & Lardner’s Top Trends for 2024 publication unpacks key developments in an uncertain regulatory landscape.
Since its inception in 1992, the 340B Drug Pricing Program (340B Program) has provided eligible health care providers (covered entities) access to significant discounts on the cost of outpatient pharmaceuticals from participating manufacturers.
Over the past 15 years, the 340B Program’s size and scope has expanded due to actions by Congress and the federal Health Resources and Services Administration (HRSA). This article provides an overview of the program's current state.
This guide provides a compilation of insights from legal practitioners around the world to assist in the identification and understanding of the laws and regulations that impact the drug and medical device industry.
In this multi-jurisdictional guide, explore an overview of key legal issues, rules and developments regarding pharmaceutical advertising across a range of jurisdictions.
This checklist can be used as a starting point for assessing legal issues in negotiation for software/technology services from a Buyer's standpoint.
Check out this whitepaper developed by Foley & Lardner LLP to learn more about the top twelve trends in the digital assets space.
Learn about top 2021 developments and 2022 predictions in the Life Sciences & Healthcare sector in China.
Check out this resource developed by Foley & Lardner LLP that focuses on the top seventeen trends for the health & life sciences sector in 2022.